One protein, two heart conditions: could atrial fibrillation and heart failure share the same cause?
Atrial fibrillation and heart failure have been treated as two separate diseases for decades. New research challenges that assumption: both conditions may stem from the same biological defect, a shortage of a single protein.
That protein is TBX5, a transcription factor, essentially a molecular switch that determines which genes are turned on or off in heart cells. Research shows that when TBX5 expression declines, the heart can fail in one of two distinct ways: the atria begin beating irregularly, or the heart's pumping capacity drops. Which outcome occurs likely depends on additional genetic and environmental factors, but in both cases the underlying trigger appears to be the same.
That may sound like a technical nuance, but the implications are significant. Together, atrial fibrillation and heart failure affect hundreds of millions of people worldwide, and current treatments are entirely different. Atrial fibrillation is managed with anticoagulants, rhythm control, or ablation, a procedure that thermally damages heart tissue to block faulty electrical signals. Heart failure is treated with ACE inhibitors, beta blockers, and diuretics. If both conditions arise from the same molecular problem, it raises an obvious question: could a therapy targeting TBX5 address both at once?
Why transcription factors are so hard to drug
TBX5 regulates the expression of a large number of other genes, making it a central hub in heart cell biology, but also a notoriously difficult drug target. Most medicines work by binding to a specific receptor or enzyme. Transcription factors typically lack that kind of clear docking site, which has historically made them hard to influence pharmacologically. So the challenge is not just whether TBX5 is the common cause, but whether that insight can actually be translated into a workable therapy.
Researchers point out that a loss of TBX5 expression may be a consequence of aging itself. It is well established that gene expression in heart cells shifts as people get older, which places this research in the broader context of age-related organ decline.
Two names, one disease?
The researchers are not calling for diagnoses to be merged, but they do argue for a rethink of treatment strategy. If the underlying pathology is the same, it may make more sense to intervene upstream, early in the biological chain, rather than continuing to fight each set of symptoms separately. How realistic that is will depend on future research into how TBX5 expression is regulated and whether it can be restored once it has declined. For now, that remains an open question.